In a lawsuit, customers allege that Centene did not provide adequate access to doctors and misrepresented coverage; a study finds the abortion pill is as safe and effective as getting the procedure in the clinic; New Hampshire considers a bill that would allow pharmacists to dispense birth control pills.
A lawsuit brought forth by customers who bought health policies from Centene alleges that the company did not provide adequate access to doctors and misrepresented its coverage. According to The New York Times, policy holders had trouble finding or could not find providers who would accept them with the policy they purchased. The lawsuit was filed in federal court in Washington State. Last month, Washington State regulators fined Centene up to $1.5 million for its insufficient network for its Affordable Care Act plans.
The abortion pill RU-486 has been around since the 1980s, but questions of its safety have lingered ever since. A new study in Peru has corroborated previous findings that at-home abortions using the pill are as safe and effective as abortions administered in the clinic, reported The Washington Post. The researchers noted that giving women around the world, particularly in countries with restrictive abortion laws, access to and information on the abortion pill can improve health outcomes and save lives.
Pharmacists in New Hampshire may be able to dispense birth control pills as the state considers a new bill. New Hampshire would join California, Oregon, and Washington if it becomes law, according to New Hampshire Union Leader. The bill calls for a creation of statewide protocols, and the deputy director of Public Health Services at the state Department of Health and Human Services explained that the bill could address the rate of unintended births, which is 4 in 10 births in New Hampshire. At least 11 other states and the District of Columbia are considering similar legislation.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More